216873-74-4

Basic information

• Product Name: [(3-bromo-4-fluorophenyl)methyl]methylamine
• Synonyms: [(3-bromo-4-fluorophenyl)methyl]methylamine
• CAS NO: 216873-74-4
• Molecular Weight: 218.069
• Mol File: 216873-74-4.mol

Chemical Properties

• CAS DataBase Reference: [(3-bromo-4-fluorophenyl)methyl]methylamine(CAS DataBase Reference)
• NIST Chemistry Reference: [(3-bromo-4-fluorophenyl)methyl]methylamine(216873-74-4)
• EPA Substance Registry System: [(3-bromo-4-fluorophenyl)methyl]methylamine(216873-74-4)

Safety Data

• Hazardous Substances Data: 216873-74-4(Hazardous Substances Data)

Upstream product

• 78239-71-1 3-bromo-4-fluorobenzyl bromide 
• 375853-85-3 (tert-butoxy)-N-[(3-bromo-4-fluorophenyl)methyl] carboxamide 
• 202865-68-7 3-bromo-4-fluoro-benzylamine hydrochloride 

Downstream Products

• 216871-25-9 trans-N-(6,6-dimethyl-2-hepten-4-ynyl)-N-methyl-(3-bromo-4-fluorobenzyl)amine 
• 216755-32-7 N-(4-tert-butylbenzyl)-N-methyl-(3-bromo-4-fluorobenzyl)amine 
• 1177558-99-4 methyl 3-{[[(3-bromo-4-fluorophenyl)methyl](methyl)amino]carbonyl}benzoate 
• 1177558-96-1 3-{[[(3-bromo-4-fluorophenyl)methyl](methyl)amino]methyl}-N-{[1,6-diethyl-4-(tetrahydro-2H-pyran-4-ylamino)-1H-pyrazolo[3,4-b]pyridin-5-yl]methyl}benzamide 

Relevant articles and documents

Dual Pharmacophores - PDE4-Muscarinic Antagonistics

The present invention is directed to novel compounds of Formula (I) and pharmaceutically acceptable salts thereof, pharmaceutical compositions and their use as dual chromaphores having inhibitory activity against PDE4 and muscarinic acetylcholine receptors (mAChRs), and thus being useful for treating respiratory diseases.

Dual Pharmacophores - PDE4-Muscarinic Antagonistics

The present invention relates to novel compounds of Formula (I) and their use in the treatment of respiratory diseases, including anti-inflammatory and allergic diseases such as chronic obstructive pulmonary disease (COPD), asthma, rhinitis (e.g. allergic rhinitis), atopic dermatitis or psoriasis.

Dual Pharmacophores - PDE4-Muscarinic Antagonistics

The present invention is directed to novel compounds of Formula (I), pharmaceutical compositions and their use in therapy, for example as inhibitors of phosphodiesterase type IV (PDE4) and as antagonists of muscarinic acetylcholine receptors (mAChRs), in the treatment of/and or prophylaxis of respiratory diseases, including antiinflammatory and/or allergic diseases such as chronic obstructive pulmonary disease (COPD), asthma, rhinitis (e.g. allergic rhinitis), atopic dermatitis or psoriasis.

DUAL PHARMACOPHORES - PDE4-MUSCARINIC ANTAGONISTICS

The present invention is directed to novel compounds of Formula's (I) - (VI), and pharmaceutically acceptable salts thereof, pharmaceutical compositions and their use in therapy, for example as inhibitors of phosphodiesterase type IV (PDE4) and as antagonists of muscarinic acetylcholine receptors (mAChRs), in the treatment of and/or prophylaxis of respiratory diseases, including inflammatory and/or allergic diseases such as chronic obstructive pulmonary disease (COPD), asthma, rhinitis (e.g. allergic rhinitis), atopic dermatitis or psoriasis.

Amine derivatives

The present invention relates to amine derivatives represented by formula (1) or salts thereof. R3represents C1-C3 alkyl, hydroxylated C1-C5 alkyl, C1-C5 acyl; C2-C5 alkenyl, or a halogen atom; and k, l, and m are each an integer of 1 to 4.) Exhibiting excellent antifungal effect, these compounds are highly useful as antifungal agents, antifungal compositions, drugs, etc.